Hexarelin

Hexarelin was developed by Europeptides (France) in the early 1990s as part of a systematic effort to improve upon the GH-releasing activity of GHRP-6. By introducing a 2-methyl substitution on the D-tryptophan at position 2 (D-2-MeTrp), researchers created a GHRP with significantly enhanced GHSR1a binding affinity and the most potent GH-releasing activity of any hexapeptide in the class. Hexarelin entered Phase 2 clinical trials for GH deficiency and growth failure in children under the name Examorelin.

Its most clinically significant differentiating feature is a GH-independent cardiac mechanism. Hexarelin binds the scavenger receptor CD36 on cardiac myocytes and vascular smooth muscle, producing direct cardioprotective effects that occur even in GH-deficient or hypophysectomized (pituitary-removed) animals. This dual receptor pharmacology — GHSR1a for GH release and CD36 for cardiac protection — is unique among GHRPs and has generated significant interest in cardiology research.

The primary limitation of Hexarelin is rapid and profound pituitary desensitisation. Unlike Ipamorelin (which maintains GH response with chronic use) or GHRP-6 (which shows moderate desensitisation), Hexarelin causes significant tachyphylaxis within days to weeks of continuous use, substantially reducing the GH response amplitude. This necessitates strict cycling protocols and makes it unsuitable for continuous long-term GH optimisation strategies. However, its extreme potency makes it valuable for short, high-intensity GH pulse applications.

// GHSR1a AGONISM — MAXIMAL GH PULSE AMPLITUDE

Hexarelin binds GHSR1a with the highest affinity of any synthetic GHRP hexapeptide — the 2-methyl group on D-Trp at position 2 enhances hydrophobic receptor pocket engagement. This produces GH pulses 2–3× greater than equimolar GHRP-6 in human studies. As with all GHRPs, the mechanism involves Gq/11-mediated intracellular Ca²⁺ mobilisation and GH vesicle exocytosis from pituitary somatotrophs. The GH pulse is further amplified by co-administration with GHRH analogues (CJC-1295).

// DIRECT CARDIAC PROTECTION VIA CD36

Hexarelin binds the scavenger receptor CD36 on cardiac myocytes and vascular smooth muscle cells — a completely distinct receptor from GHSR1a. This GH-independent cardiac mechanism activates ERK1/2 and PI3K/Akt survival pathways, protecting cardiomyocytes from ischaemia-reperfusion injury, reducing infarct size, improving post-ischaemic cardiac function, and promoting angiogenesis in the ischaemic myocardium. Studies in hypophysectomised animals confirm this effect persists without pituitary function — proving it is independent of GH release.

// CORTISOL & PROLACTIN CO-STIMULATION

Like GHRP-6, Hexarelin stimulates ACTH/cortisol and prolactin release at therapeutic doses via GHSR1a in the hypothalamus and pituitary. These transient hormonal spikes are more pronounced than with Ipamorelin but generally well-tolerated at standard research doses. Cortisol elevation is not clinically significant at typical doses but represents a distinction from selective GHRPs.

// RAPID PITUITARY DESENSITISATION

Hexarelin's exceptional GHSR1a binding affinity is a double-edged sword: it also drives rapid receptor internalisation and downregulation. Continuous Hexarelin administration causes significant pituitary desensitisation within 4–14 days, reducing subsequent GH responses by 50–80%. This tachyphylaxis is more rapid and severe than GHRP-6 or GHRP-2. Recovery requires 4+ weeks off-cycle. This pharmacological limitation is the primary reason Hexarelin has not supplanted Ipamorelin in long-term protocols despite its superior acute GH-releasing potency.

Clinical trials (Europeptides / Pharmacia): Hexarelin (Examorelin) completed Phase 2 trials in GH-deficient adults and children with short stature. Results confirmed dose-dependent GH release and IGF-1 elevation, but desensitisation during extended dosing limited its development as a chronic therapy. No regulatory approvals were obtained; development was discontinued in favour of oral GHS compounds (MK-677/Ibutamoren).

Cardiac studies: The discovery of CD36-mediated cardioprotection (Broglio, Ghigo et al., 2002) opened a new research direction. In isolated heart preparations and animal ischaemia models, Hexarelin consistently reduced infarct size and improved post-ischaemic recovery independent of GH. Small human studies in patients with ischaemic cardiomyopathy showed improvements in left ventricular function after Hexarelin infusion. This cardiac application remains an active but underfunded research area.

Comparison to other GHRPs: Head-to-head studies place Hexarelin GH-releasing potency as: Hexarelin > GHRP-2 > GHRP-6 > Ipamorelin. However, for sustained use, Ipamorelin remains superior due to its selectivity (no cortisol/prolactin) and resistance to desensitisation.